Minireview: Live and let die: Molecular effects of glucocorticoids on bone cells

Molecular Endocrinology

Volumn 23, Issue 10, 2009, Pages 1525-1531

  Hofbauer, Lorenz C ^a   Rauner, Martina ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; AL 438; BI 115; COMOUND 25; COMPOUND 15; COMPOUND 25; COMPOUND 28; COMPOUND 60; COMPOUND A; DENOSUMAB; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; HORMONE RECEPTOR STIMULATING AGENT; LGD 5552; PARATHYROID HORMONE[1-34]; PREDNISOLONE; RISEDRONIC ACID; RU 24858; UNCLASSIFIED DRUG;

APOPTOSIS; BONE CELL; BONE REMODELING; CELL FUNCTION; CELL MATURATION; DISEASE PREDISPOSITION; GENE REPRESSION; GENE TARGETING; HUMAN; INFLAMMATION; MOLECULAR DYNAMICS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOPOROSIS; OTITIS; PAW EDEMA; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; BONE REMODELING; DISEASE SUSCEPTIBILITY; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; RECEPTORS, GLUCOCORTICOID;

EID: 70349774455     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0069     Document Type: Short Survey

References (51)

1. Schäcke H, Döcke WD, Asadullah K 2002 Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96:23-43 (Pubitemid 35346616)
2. Manolagas SC, Weinstein RS 1999 New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14:1061-1066 (Pubitemid 29314048)
3. Cooper C, Coupland C, Mitchell M 1995 Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 54:49-52
4. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN 2000 Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 160:2917-2922 (Pubitemid 32009048)
5. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C 2003 Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224-3229 (Pubitemid 37409336)
6. Cherian PP, Xia X, Jiang JX 2008 Role of gap junction, hemichannels, and connexin 43 in mineralizing in response to intermittent and continuous application of parathyroid hormone. Cell Commun Adhes 15:43-54
7. Rauner M, Sipos W, Pietschmann P 2007 Osteoimmunology. Int Arch Allergy Immunol 143:31-48
8. Hofbauer LC, Schoppet M 2004 Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490-495 (Pubitemid 38988958)
9. Song IH, Buttgereit F 2006 Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol 246:142-146 (Pubitemid 43238408)
10. Beavan S, Horner A, Bord S, Ireland D, Compston J 2001 Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res 16:1496-1504 (Pubitemid 32675201)
11. Schäcke H, Berger M, Rehwinkel H, Asadullah K 2007 Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 275:109-117 (Pubitemid 47259282)
12. Lewis-Tuffin LJ, Jewell CM, Bienstock RJ, Collins JB, Cidlowski JA 2007 Human glucocorticoid receptor β binds RU-486 and is transcriptionally active. Mol Cell Biol 27:2266-2282
13. Honda M, Orii F, Ayabe T, Imai S, Ashida T, Obara T, Kohgo Y 2000 Expression of glucocorticoid receptor β in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 118:859-866 (Pubitemid 30243749)
14. Orii F, Ashida T, Nomura M, Maemoto A, Fujiki T, Ayabe T, Imai S, Saitoh Y, Kohgo Y 2002 Quantitative analysis for human glucocorticoid receptor α/β mRNA in IBD. Biochem Biophys Res Commun 296:1286-1294
15. Canalis E, Mazziotti G, Giustina A, Bilezikian JP 2007 Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328
16. Dempster DW 1989 Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 4:137-141
17. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274-282
18. Eijken M, Hewison M, Cooper MS, de Jong FH, Chiba H, Stewart PM, Uitterlinden AG, Pols HA, van Leeuwen JP 2005 11β-Hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation. Mol Endocrinol 19:621-631 (Pubitemid 40349436)
19. Sher LB, Woitge HW, Adams DJ, Gronowicz GA, Krozowski Z, Harrison JR, Kream BE 2004 Transgenic expression of 11β-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone. Endocrinology 145:922-929 (Pubitemid 38183836)
20. Shi XM, Blair HC, Yang X, McDonald JM, Cao X 2000 Tandem repeat of C/EBP binding sites mediates PPARγ2 gene transcription in glucocorticoid-induced adipocyte differentiation. J Cell Biochem 76:518-527 (Pubitemid 30078460)
21. Vande Berg BC, Malghem J, Lecouvet FE, Devogelaer JP, Maldague B, Houssiau FA 1999 Fat conversion of femoral marrow in glucocorticoid-treated patients: a cross-sectional and longitudinal study with magnetic resonance imaging. Arthritis Rheum 42:1405-1411 (Pubitemid 30265598)
22. Zhang W, Yang N, Shi XM 2008 Regulation of mesenchymal stem cell osteogenic differentiation by glucocorticoid-induced leucine zipper (GILZ). J Biol Chem 283:4723-4729
23. Hamidouche Z, Haÿ E, Vaudin P, Charbord P, Schüle R, Marie PJ, Fromigué O 2008 FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/β-catenin signaling-dependent Runx2 expression. FASEB J 22:3813-3822
24. Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL 2008 Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 149:1793-1801
25. Zhou H, Mak W, Kalak R, Street J, Fong-Yee C, Zheng Y, Dunstan CR, Seibel MJ 2009 Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development 136:427-436
26. Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO, Lane NE 2008 Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 58:3485-3497
27. Kogianni G, Mann V, Ebetino F, Nuttall M, Nijweide P, Simpson H, Noble B 2004 Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis. Life Sci 75:2879-2895 (Pubitemid 39349254)
28. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS 2004 Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835-1841 (Pubitemid 38402392)
29. Espina B, Liang M, Russell RG, Hulley PA 2008 Regulation of bim in glucocorticoid-mediated osteoblast apoptosis. J Cell Physiol 215:488-496
30. Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T 2008 Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 23:1712-1721
31. Jørgensen NR, Teilmann SC, Henriksen Z, Meier E, Hansen SS, Jensen JE, Sørensen OH, Petersen JS 2005 The antiarrhythmic peptide analog rotigaptide (ZP123) stimulates gap junction intercellular communication in human osteoblasts and prevents decrease in femoral trabecular bone strength in ovariectomized rats. Endocrinology 146:4745-4754
32. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S 1999 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382-4389 (Pubitemid 30666099)
33. Kondo T, Kitazawa R, Yamaguchi A, Kitazawa S 2008 Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem 103:335-345
34. Hofbauer LC, Zeitz U, Schoppet M, Skalicky M, Schüler C, Stolina M, Kostenuik PJ, Erben RG 2009 Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum 60:1427-1437
35. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS 2006 Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147:5592-5599 (Pubitemid 44833476)
36. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL 2006 Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116:2152-2160 (Pubitemid 44162324)
37. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM 2004 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25:831-866 (Pubitemid 39366049)
38. Diederich S, Eigendorff E, Burkhardt P, Quinkler M, Bumke-Vogt C, Rochel M, Seidelmann D, Esperling P, Oelkers W, Bähr V 2002 11-Hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 87:5695-5701 (Pubitemid 36034378)
39. Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin CW, Elmore SW, Kym PR, Luly JR, Carter GW, Turner R, Tyree CM, Hu J, Elgort M, Rosen J, Miner JN 2003 A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol 17:860-869 (Pubitemid 36546214)
40. Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K 2004 Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 101:227-232 (Pubitemid 38084232)
41. Humphrey EL, Williams JH, Davie MW, Marshall MJ 2006 Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 38:652-661
42. Owen HC, Miner JN, Ahmed SF, Farquharson C 2007 The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol 264:164-170 (Pubitemid 46097311)
43. Kuzmich D, Kirrane T, Proudfoot J, Bekkali Y, Zindell R, Beck L, Nelson R, Shih CK, Kukulka AJ, Paw Z, Reilly P, Deleon R, Cardozo M, Nabozny G, Thomson D 2007 Identification of dissociated nonsteroidal glucocorticoid receptor agonists. Bioorg Med Chem Lett 17:5025-5031 (Pubitemid 47259678)
44. Dewint P, Gossye V, De Bosscher K, Vanden Berghe W, Van Beneden K, Deforce D, Van Calenbergh S, Müller-Ladner U, Vander Cruyssen B, Verbruggen G, Haegeman G, Elewaut D 2008 A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol 180:2608-2615
45. De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, Hapgood J, Libert C, Staels B, Louw A, Haegeman G 2005 A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA 102:15827-15832 (Pubitemid 41552827)
46. Thompson CF, Quraishi N, Ali A, Tata JR, Hammond ML, Balkovec JM, Einstein M, Ge L, Harris G, Kelly TM, Mazur P, Pandit S, Santoro J, Sitlani A, Wang C, Williamson J, Miller DK, Yamin TT, Thompson CM, O'Neill EA, Zaller D, Forrest MJ, Carballo-Jane E, Luell S 2005 Novel heterocyclic glucocorticoids: in vitro profile and in vivo efficacy. Bioorg Med Chem Lett 15:2163-2167 (Pubitemid 40445486)
47. Shah N, Scanlan TS 2004 Design and evaluation of novel nonsteroidal dissociating glucocorticoid receptor ligands. Bioorg Med Chem Lett 14:5199-5203 (Pubitemid 39233394)
48. Smith CJ, Ali A, Balkovec JM, Graham DW, Hammond ML, Patel GF, Rouen GP, Smith SK, Tata JR, Einstein M, Ge L, Harris GS, Kelly TM, Mazur P, Thompson CM, Wang CF, Williamson JM, Miller DK, Pandit S, Santoro JC, Sitlani A, Yamin TT, O'Neill EA, Zaller DM, Carballo-Jane E, et al. 2005 Novel ketal ligands for the glucocorticoid receptor: in vitro and in vivo activity. Bioorg Med Chem Lett 15:2926-2931 (Pubitemid 40732249)
49. Barker M, Clackers M, Copley R, Demaine DA, Humphreys D, Inglis GG, Johnston MJ, Jones HT, Haase MV, House D, Loiseau R, Nisbet L, Pacquet F, Skone PA, Shanahan SE, Tape D, Vinader VM, Washington M, Uings I, Upton R, McLay IM, Macdonald SJ 2006 Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series. J Med Chem 49:4216-4231 (Pubitemid 44036665)
50. López FJ, Ardecky RJ, Bebo B, Benbatoul K, De Grandpre L, Liu S, Leibowitz MD, Marschke K, Rosen J, Rungta D, Viveros HO, Yen WC, Zhi L, Negro-Vilar A, Miner JN 2008 LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo. Endocrinology 149:2080-2089 (Pubitemid 351574480)
51. Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE, Woodman P, Brown TJ, Webber SE, Foster ML 2001 Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 166:1975-1982 (Pubitemid 32114685)